Power of compounding intravitreal Bevacizumab - Experience from a tertiary eye care hospital
Santosh Ramesh, S Sivaranjani, Nirav Zala Hasmukhbhai and 1 more
Indian Journal of Ophthalmology · 2022
doi:10.4103/ijo.ijo_1016_22 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Background: Bevacizumab vials that are commercially available are fractionated into smaller quantities into the form of pre-filled syringes in a sterile and aseptic laboratory setting. Purpose: To share the long term experience of aliquoting of bevacizumab injections in a tertiary eye care center in India. Synopsis: Compounding of bevacizumab was found to be a cost-effective and sustainable practice that has benefited more patients with an affordable cost, while maintaining high levels of quality. Highlights: Compounding of bevacizumab, when done with aseptic precautions can be a safe and cost-effective practice, the benefits of which can be passed on to needful patients. Video Link: https://youtu.be/C5XOpKHFkew
Abstract licence: CC BY-NC-SA
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.